These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 20660830

  • 1. Phase II randomized comparison of topotecan plus cyclophosphamide versus topotecan alone in children with recurrent or refractory neuroblastoma: a Children's Oncology Group study.
    London WB, Frantz CN, Campbell LA, Seeger RC, Brumback BA, Cohn SL, Matthay KK, Castleberry RP, Diller L.
    J Clin Oncol; 2010 Aug 20; 28(24):3808-15. PubMed ID: 20660830
    [Abstract] [Full Text] [Related]

  • 2. Treatment with topotecan plus cyclophosphamide in children with first relapse of neuroblastoma.
    Ashraf K, Shaikh F, Gibson P, Baruchel S, Irwin MS.
    Pediatr Blood Cancer; 2013 Oct 20; 60(10):1636-41. PubMed ID: 23650219
    [Abstract] [Full Text] [Related]

  • 3. Response to paclitaxel, topotecan, and topotecan-cyclophosphamide in children with untreated disseminated neuroblastoma treated in an upfront phase II investigational window: a pediatric oncology group study.
    Kretschmar CS, Kletzel M, Murray K, Thorner P, Joshi V, Marcus R, Smith EI, London WB, Castleberry R.
    J Clin Oncol; 2004 Oct 15; 22(20):4119-26. PubMed ID: 15483021
    [Abstract] [Full Text] [Related]

  • 4. Phase II study of temozolomide in combination with topotecan (TOTEM) in relapsed or refractory neuroblastoma: a European Innovative Therapies for Children with Cancer-SIOP-European Neuroblastoma study.
    Di Giannatale A, Dias-Gastellier N, Devos A, Mc Hugh K, Boubaker A, Courbon F, Verschuur A, Ducassoul S, Malekzadeh K, Casanova M, Amoroso L, Chastagner P, Zwaan CM, Munzer C, Aerts I, Landman-Parker J, Riccardi R, Le Deley MC, Geoerger B, Rubie H.
    Eur J Cancer; 2014 Jan 15; 50(1):170-7. PubMed ID: 24021349
    [Abstract] [Full Text] [Related]

  • 5. Clinical outcomes and prognostic factors to predict treatment response in high risk neuroblastoma patients receiving topotecan and cyclophosphamide containing induction regimen: a prospective multicenter study.
    Rujkijyanont P, Photia A, Traivaree C, Monsereenusorn C, Anurathapan U, Seksarn P, Sosothikul D, Techavichit P, Sanpakit K, Phuakpet K, Wiangnon S, Chotsampancharoen T, Chainansamit SO, Kanjanapongkul S, Meekaewkunchorn A, Hongeng S.
    BMC Cancer; 2019 Oct 16; 19(1):961. PubMed ID: 31619207
    [Abstract] [Full Text] [Related]

  • 6. Topotecan and cyclophosphamide in patients with refractory or relapsed Ewing tumors.
    Hunold A, Weddeling N, Paulussen M, Ranft A, Liebscher C, Jürgens H.
    Pediatr Blood Cancer; 2006 Nov 16; 47(6):795-800. PubMed ID: 16411206
    [Abstract] [Full Text] [Related]

  • 7. Topotecan, cyclophosphamide, and etoposide (TCE) in the treatment of high-risk neuroblastoma. Results of a phase-II trial.
    Simon T, Längler A, Harnischmacher U, Frühwald MC, Jorch N, Claviez A, Berthold F, Hero B.
    J Cancer Res Clin Oncol; 2007 Sep 16; 133(9):653-61. PubMed ID: 17479288
    [Abstract] [Full Text] [Related]

  • 8. Outcomes of the POG 9340/9341/9342 trials for children with high-risk neuroblastoma: a report from the Children's Oncology Group.
    Zage PE, Kletzel M, Murray K, Marcus R, Castleberry R, Zhang Y, London WB, Kretschmar C, Children's Oncology Group.
    Pediatr Blood Cancer; 2008 Dec 16; 51(6):747-53. PubMed ID: 18704922
    [Abstract] [Full Text] [Related]

  • 9. Outcome of children with relapsed or refractory neuroblastoma: A meta-analysis of ITCC/SIOPEN European phase II clinical trials.
    Moreno L, Rubie H, Varo A, Le Deley MC, Amoroso L, Chevance A, Garaventa A, Gambart M, Bautista F, Valteau-Couanet D, Geoerger B, Vassal G, Paoletti X, Pearson AD.
    Pediatr Blood Cancer; 2017 Jan 16; 64(1):25-31. PubMed ID: 27555472
    [Abstract] [Full Text] [Related]

  • 10. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study.
    Saylors RL, Stewart CF, Zamboni WC, Wall DA, Bell B, Stine KC, Vietti TJ.
    J Clin Oncol; 1998 Mar 16; 16(3):945-52. PubMed ID: 9508177
    [Abstract] [Full Text] [Related]

  • 11. Safety, tolerability and pharmacokinetics of crizotinib in combination with cytotoxic chemotherapy for pediatric patients with refractory solid tumors or anaplastic large cell lymphoma (ALCL): a Children's Oncology Group phase 1 consortium study (ADVL1212).
    Greengard E, Mosse YP, Liu X, Minard CG, Reid JM, Voss S, Wilner K, Fox E, Balis F, Blaney SM, Adamson PC, Weigel BJ.
    Cancer Chemother Pharmacol; 2020 Dec 16; 86(6):829-840. PubMed ID: 33095287
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Topotecan plus cyclophosphamide as maintenance chemotherapy for children with high-risk neuroblastoma in complete remission: short-term curative effects and toxicity.
    Feng C, Tang S, Wang J, Liu Y, Yang G.
    Nan Fang Yi Ke Da Xue Xue Bao; 2013 Aug 16; 33(8):1107-10. PubMed ID: 23996746
    [Abstract] [Full Text] [Related]

  • 17. Gefitinib in combination with oral topotecan and cyclophosphamide in relapsed neuroblastoma: pharmacological rationale and clinical response.
    Donfrancesco A, De Ioris MA, McDowell HP, De Pasquale MD, Ilari I, Jenkner A, Castellano A, Cialfi S, De Laurentis C, Dominici C.
    Pediatr Blood Cancer; 2010 Jan 16; 54(1):55-61. PubMed ID: 19821523
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Short topotecan-based induction regimen in newly diagnosed high-risk neuroblastoma.
    De Ioris MA, Castellano A, Ilari I, Garganese MC, Natali G, Inserra A, De Vito R, Ravà L, De Pasquale MD, Locatelli F, Donfrancesco A, Jenkner A.
    Eur J Cancer; 2011 Mar 16; 47(4):572-8. PubMed ID: 21112775
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.